Literature DB >> 33441885

Increased infiltration of regulatory T cells in hepatocellular carcinoma of patients with hepatitis B virus pre-S2 mutant.

Chiao-Fang Teng1,2,3, Tsai-Chung Li4,5, Ting Wang6, Da-Ching Liao7, Yi-Hsuan Wen7, Tzu-Hua Wu6, John Wang8, Han-Chieh Wu9, Woei-Cherng Shyu10,11,12,13, Ih-Jen Su14, Long-Bin Jeng15.   

Abstract

Hepatocellular carcinoma (HCC) is a frequent and deadly human cancer worldwide that is intimately associated with chronic hepatitis B virus (HBV) infection. Pre-S2 mutant is a HBV oncoprotein that plays important roles in HCC development and is linked to poor prognosis in HCC patients. However, the profiles of tumor-infiltrating lymphocytes in HCC tissues of pre-S2 mutant-positive patients remain unknown. In this study, we performed fluorescent immunohistochemistry staining to detect the infiltration of 'anti-tumor' cytotoxic T lymphocytes (CTLs) and 'pro-tumor' regulatory T cells (Tregs) in pre-S2 mutant-positive and -negative HCC patients. We showed that pre-S2 mutant-positive patients had a significantly higher infiltration of CD4+CD25+ cells and forkhead box P3 (Foxp3)-expressing cells but similar CTLs and lower granzyme B-expressing cells in HCC tissues compared with pre-S2 mutant-negative patients. Moreover, the percentage of pre-S2 plus pre-S1 + pre-S2 deletion (pre-S2 mutant) was positively correlated with the density of CD4+CD25+ cells and Foxp3-expressing cells but negatively with granzyme B-expressing cells in HCC tissues. Considering that increased intratumoral Tregs have been shown to promote tumor immune evasion, our data may provide new insights into the pathogenesis of HBV pre-S2 mutant-induced HCC and suggest that therapeutics targeting Tregs may be a promising strategy for treating pre-S2 mutant-positive high-risk patient population.

Entities:  

Year:  2021        PMID: 33441885      PMCID: PMC7807072          DOI: 10.1038/s41598-020-80935-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  55 in total

1.  Tumor-derived transforming growth factor-β is critical for tumor progression and evasion from immune surveillance.

Authors:  Zheng Li; Li-Juan Zhang; Hong-Ru Zhang; Gao-Fei Tian; Jun Tian; Xiao-Li Mao; Zheng-Hu Jia; Zi-Yu Meng; Li-Qing Zhao; Zhi-Nan Yin; Zhen-Zhou Wu
Journal:  Asian Pac J Cancer Prev       Date:  2014

Review 2.  The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective.

Authors:  Alan P Venook; Christos Papandreou; Junji Furuse; Laura Ladrón de Guevara
Journal:  Oncologist       Date:  2010

Review 3.  Targeting Treg cells in cancer immunotherapy.

Authors:  Atsushi Tanaka; Shimon Sakaguchi
Journal:  Eur J Immunol       Date:  2019-07-05       Impact factor: 5.532

4.  TGFbeta regulates the CD4+CD25+ T-cell pool and the expression of Foxp3 in vivo.

Authors:  Christoph Schramm; Samuel Huber; Martina Protschka; P Czochra; Jürgen Burg; Edgar Schmitt; Ansgar W Lohse; Peter R Galle; Manfred Blessing
Journal:  Int Immunol       Date:  2004-07-12       Impact factor: 4.823

5.  Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress.

Authors:  Hui-Ching Wang; Han-Chieh Wu; Chien-Fu Chen; Nelson Fausto; Huan-Yao Lei; Ih-Jen Su
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

6.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

7.  Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems.

Authors:  Po-Hong Liu; Chia-Yang Hsu; Cheng-Yuan Hsia; Yun-Hsuan Lee; Chien-Wei Su; Yi-Hsiang Huang; Fa-Yauh Lee; Han-Chieh Lin; Teh-Ia Huo
Journal:  J Hepatol       Date:  2015-11-11       Impact factor: 25.083

8.  Next-Generation Sequencing-Based Quantitative Detection of Hepatitis B Virus Pre-S Mutants in Plasma Predicts Hepatocellular Carcinoma Recurrence.

Authors:  Chiao-Fang Teng; Tsai-Chung Li; Hsi-Yuan Huang; Jia-Hui Lin; Wen-Shu Chen; Woei-Cherng Shyu; Han-Chieh Wu; Cheng-Yuan Peng; Ih-Jen Su; Long-Bin Jeng
Journal:  Viruses       Date:  2020-07-24       Impact factor: 5.048

9.  Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.

Authors:  Hung-Wen Tsai; Yih-Jyh Lin; Han-Chieh Wu; Ting-Tsung Chang; I-Chin Wu; Pin-Nan Cheng; Chia-Jui Yen; Shih-Huang Chan; Wenya Huang; Ih-Jen Su
Journal:  Oncotarget       Date:  2016-05-10

Review 10.  From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.

Authors:  Yaojie Fu; Shanshan Liu; Shan Zeng; Hong Shen
Journal:  J Exp Clin Cancer Res       Date:  2019-09-09
View more
  6 in total

1.  HBV preS Mutations Promote Hepatocarcinogenesis by Inducing Endoplasmic Reticulum Stress and Upregulating Inflammatory Signaling.

Authors:  Wenbin Liu; Shiliang Cai; Rui Pu; Zixiong Li; Donghong Liu; Xinyu Zhou; Jianhua Yin; Xi Chen; Liping Chen; Jianfeng Wu; Xiaojie Tan; Xin Wang; Guangwen Cao
Journal:  Cancers (Basel)       Date:  2022-07-04       Impact factor: 6.575

2.  Association of Increased Programmed Death Ligand 1 Expression and Regulatory T Cells Infiltration with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection.

Authors:  Long-Bin Jeng; Tsai-Chung Li; Shih-Chao Hsu; Chiao-Fang Teng
Journal:  Viruses       Date:  2022-06-20       Impact factor: 5.818

Review 3.  Approaches for Detection of Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins and Their Application in Prediction of Higher Risk of Hepatocellular Carcinoma Development and Recurrence.

Authors:  Yueh-Te Lin; Long-Bin Jeng; Ih-Jen Su; Chiao-Fang Teng
Journal:  Viruses       Date:  2022-02-18       Impact factor: 5.048

Review 4.  Tertiary Lymphatic Structures in Primary Hepatic Carcinoma: Controversy Cannot Overshadow Hope.

Authors:  Weili Jia; Tianchen Zhang; Qianyun Yao; Jianhui Li; Ye Nie; Xinjun Lei; Zhenzhen Mao; Yanfang Wang; Wen Shi; Wenjie Song
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

Review 5.  Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression.

Authors:  Arshi Khanam; Joel V Chua; Shyam Kottilil
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

Review 6.  Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins: Clinical and Molecular Implications in Hepatocellular Carcinoma.

Authors:  Yueh-Te Lin; Long-Bin Jeng; Wen-Ling Chan; Ih-Jen Su; Chiao-Fang Teng
Journal:  Viruses       Date:  2021-05-08       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.